Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical immunotherapy for brain tumors.

Peter E Fecci1, John H Sampson

  • 1Departments of Neurosurgery and Pathology, Duke University Medical Center, Durham, NC 27710, USA.

Neuroimaging Clinics of North America
|April 12, 2003
PubMed
Summary

Dendritic cells offer a safe and tumor-specific immunization strategy for brain tumors, overcoming common immunologic challenges. Further research will optimize their use for effective immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain Metastases.

Advances in radiation oncology·2026
Same author

Identifying predictive factors for radiation necrosis vs local recurrence in biopsy-proven enlarging lesions post-stereotactic radiosurgery for brain metastases.

Neuro-oncology practice·2026
Same author

Laser Interstitial Thermal Therapy for Brain Metastases: Imaging Guidelines for Clinical Trials and Practice.

Neuro-oncology·2026
Same author

IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma.

Journal for immunotherapy of cancer·2026
Same author

Contemporary Management of Radiation Necrosis: Insights and Avenues.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Impact of systemic therapy after stereotactic radiosurgery in patients with limited brain-only metastasis.

Neuro-oncology advances·2026

Area of Science:

  • Neuro-oncology
  • Immunotherapy
  • Cellular therapy

Background:

  • Brain tumors, particularly gliomas, present significant challenges for current therapeutic options.
  • Existing immunotherapies often struggle to overcome the unique immunologic barriers of the central nervous system (CNS).
  • Dendritic cells (DCs) are fundamental antigen-presenting cells with potential as an immunization platform.

Purpose of the Study:

  • To highlight the advantages of dendritic cells as an immunization platform for brain tumors.
  • To discuss the potential of DCs in overcoming CNS-specific immunologic challenges.
  • To outline future research directions for optimizing DC-based brain tumor immunotherapy.

Main Methods:

  • Review of existing literature on dendritic cell biology and immunotherapy for brain tumors.
  • Analysis of the immunologic challenges posed by gliomas and the CNS.
  • Identification of key areas for future preclinical and clinical research.

Main Results:

  • Dendritic cells offer safety and tumor-specificity, desirable traits for brain tumor therapeutics.
  • DCs can circumvent many immunologic hurdles that impede other immunotherapeutic approaches in the CNS.
  • Preclinical studies are crucial for refining DC-based active immunotherapy strategies.

Conclusions:

  • Dendritic cells represent a promising immunization platform for brain tumors due to their inherent properties.
  • Optimizing DC subtype, generation, loading, maturation, dose, and delivery are critical next steps.
  • Continued preclinical research is essential for advancing DC-based immunotherapy for brain tumors.

Related Experiment Videos